Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Roundup: WHO Releases Draft Guideline For Production And Control Of Specified Starting Materials.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Regulatory Roundup

According to a release from Rx-360, the international pharmaceutical supply-chain consortium, the World Health Organization has released for comment a draft guideline for the production and control of specified starting materials. The draft, currently released to only a specified audience, defines starting materials as “any substance which is primarily or mainly used as a starting material for the production of an API [active pharmaceutical ingredient], but which itself could be used directly as an API” and notes that the specified starting material should therefore “conform to the existing monograph in a recognized pharmacopeia.” If the material is to be used for API production, however, then the “quality attributes and specifications should be determined by the API manufacturer” and the product’s intended use, according to RX-360’s release on the guideline. Quality control for starting materials should include test for impurities, isomers, residual solvents, and other impurities and take a risk-based approach. The consortium has a full summary on its website.

 

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here